News | January 22, 2022
Molnupiravir reduces risk of hospitalisation by 30% : Dr Shashank Joshi
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
Previously, the use of the drug was limited to patients requiring hospitalization
UCB plans to submit regulatory applications in Q3 2022
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Biocon has reported consolidated financial results for the period ended December 31, 2021
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
First launches expected in H1 2022
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Subscribe To Our Newsletter & Stay Updated
